RZLT
Rezolute, Inc.
$4.25
-5.76%
$409.2M
No data for this timeframe.
Vol
Market Cap$409.2M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (75%)
Inst. Holders7 funds
Inst. Value$32.5M
Inst. Activity4 buys / 1 sells
Insider Activity1B / 0S
Insider Net $$28.5K
SEC Reports5
Press Releases1
Recent Activity
Jun 2, 2026
SEC
Rezolute announced positive interim data from its Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism. 6 of 8 enr
8-K — Impact 7/10
May 12, 2026
SEC
Rezolute reported Q3 fiscal 2026 results with a net loss of $16.2M ($-0.16/share), narrower than the $18.9M loss ($-0.27
8-K — Impact 5/10
May 12, 2026
SEC
Rezolute reported Q3 FY2026 EPS of -$0.16 (GAAP), a 30.5% miss vs consensus of -$0.17, with zero revenue. The miss was d
PRESS-RELEASE — Impact 6/10
Mar 30, 2026
Insider
Evans Daron bought 10,000 shares
CFO @ $2.85 ($28.5K)
Mar 2, 2026
Insider
Evans Daron sold 11,438 shares
CFO @ $2.99 ($34.2K)
Mar 2, 2026
Insider
ROBERTS BRIAN KENNETH sold 11,439 shares
Chief Medical Officer @ $2.99 ($34.2K)
Inst.
BANK OF AMERICA CORP — DOUBLED
4,325,248 shares ($10.2M)
Inst.
FMR LLC — NEAR_EXIT
2,305,568 shares ($5.4M)
Price Targets
$7.11
+67.3% upside
Strong Buy
Current $4.25
Low $4.00
Median $6.00
High $14.00
9 analysts
$4.00
$14.00
Analyst Ratings
6Strong Buy
6Buy
4Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 3, 2026 | Maxim Group | MAINTAIN | Buy → Buy |
| Jun 3, 2026 | Citizens | UPGRADE | Market Perform → Market Outperform |
| Jun 3, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| Jun 2, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Jun 2, 2026 | BTIG | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Next Q | $-0.16 ▲ +20.0% | $-0.22 — $-0.12 | 12% YoY | 6 |
| Next FY | $-0.63 | $-0.87 — $-0.45 | 10% YoY | 8 |
| Current Q | $-0.14 | $-0.17 — $-0.11 | 45% YoY | 8 |
| Current FY | $-0.69 | $-0.72 — $-0.67 | 29% YoY | 8 |
Latest Reports
NEUTRAL
Press
3/10
Rezolute announced four presentations at the ENDO 2026 conference, including an oral presentation of previously reported
Jun 4, 2026
BULLISH
8-K
7/10
Rezolute announced positive interim data from its Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism. 6 of 8 enr
Jun 2, 2026
NEUTRAL
8-K
5/10
Rezolute reported Q3 fiscal 2026 results with a net loss of $16.2M ($-0.16/share), narrower than the $18.9M loss ($-0.27
May 12, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $11.3M | ADD |
| BANK OF AMERICA CORP | $10.2M | DOUBLED |
| FMR LLC | $5.4M | NEAR_EXIT |
| MORGAN STANLEY | $3.6M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $1.6M | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 30, 2026 | Evans Daron | BUY | $28.5K |
| Mar 2, 2026 | Evans Daron | F | $34.2K |
| Mar 2, 2026 | ROBERTS BRIAN | F | $34.2K |
| Mar 2, 2026 | Elam Nevan | F | $82.6K |
7 institutional holders with $32.5M total value (13,782,030 shares) as of 2025-Q4. Top holders: VANGUARD, BANK, FMR. Net buying activity: 4 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 4,788,511 | $11.3M | 34.7% | ADD +69.3% |
| 2 | BANK OF AMERICA CORP /DE/ | 4,325,248 | $10.2M | 31.4% | DOUBLED +236.6% |
| 3 | FMR LLC | 2,305,568 | $5.4M | 16.7% | NEAR_EXIT -81.9% |
| 4 | MORGAN STANLEY | 1,516,435 | $3.6M | 11.0% | DOUBLED +348.8% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 665,158 | $1.6M | 4.8% | DOUBLED +220.3% |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 91,461 | $215.8K | 0.7% | NEW |
| 7 | WELLS FARGO & COMPANY/MN | 89,649 | $211.6K | 0.7% | ADD +82.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | DOUBLED | 1,284,962 | 4,325,248 | +236.6% | $10.2M | 2025-Q4 |
| FMR LLC | NEAR_EXIT | 12,764,233 | 2,305,568 | -81.9% | $5.4M | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 337,920 | 1,516,435 | +348.8% | $3.6M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 91,461 | — | $215.8K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 49,136 | 89,649 | +82.5% | $211.6K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 76,554 | 1,284,962 | +1578.5% | $12.1M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 203,581 | 652,139 | +220.3% | $6.1M | 2025-Q3 |
| MORGAN STANLEY | ADD | 237,153 | 337,920 | +42.5% | $3.2M | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 35,742 | 49,136 | +37.5% | $461.9K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 52,833 | 0 | -100.0% | $0.00 | 2025-Q3 |
| FMR LLC | ADD | 6,507,718 | 12,811,876 | +96.9% | $57.1M | 2025-Q2 |
| VANGUARD GROUP INC | ADD | 2,375,378 | 4,022,580 | +69.3% | $17.9M | 2025-Q2 |
| UBS Group AG | DOUBLED | 616,515 | 3,037,168 | +392.6% | $13.5M | 2025-Q2 |
| MORGAN STANLEY | ADD | 156,319 | 237,153 | +51.7% | $1.1M | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 22,757 | 203,581 | +794.6% | $908.0K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 572,695 | 76,554 | -86.6% | $341.4K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 378,800 | 52,833 | -86.1% | $235.6K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEW | — | 35,742 | — | $159.4K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 42,531 | 0 | -100.0% | $0.00 | 2025-Q2 |
| FMR LLC | NEW | — | 6,507,718 | — | $18.9M | 2025-Q1 |
| UBS Group AG | ADD | 331,799 | 616,515 | +85.8% | $1.8M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 89,700 | 378,800 | +322.3% | $1.1M | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 54,948 | 156,319 | +184.5% | $453.3K | 2025-Q1 |
| CITADEL ADVISORS LLC | TRIM | 328,132 | 116,991 | -64.3% | $339.3K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 59,463 | 42,531 | -28.5% | $123.3K | 2025-Q1 |
3 unique insiders with 1 transactions. Net insider value: $28.5K ($28.5K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 30, 2026 | Evans Daron | CFO | BUY | 10,000 | $2.85 | $28.5K |
| Mar 2, 2026 | Evans Daron | CFO | F | 11,438 | $2.99 | $34.2K |
| Mar 2, 2026 | ROBERTS BRIAN KENNETH | Chief Medical Officer | F | 11,439 | $2.99 | $34.2K |
| Mar 2, 2026 | Elam Nevan C | CEO | F | 27,618 | $2.99 | $82.6K |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 1 mixed, 1 neutral. Avg impact: 5.6/10.
BULLISH
8-K
7/10
Rezolute announced positive interim data from its Phase 3 upLIFT study of ersodetug in tumor hyperin
Jun 2, 2026
NEUTRAL
8-K
5/10
Rezolute reported Q3 fiscal 2026 results with a net loss of $16.2M ($-0.16/share), narrower than the
May 12, 2026
BEARISH
PRESS-RELEASE
6/10
Rezolute reported Q3 FY2026 EPS of -$0.16 (GAAP), a 30.5% miss vs consensus of -$0.17, with zero rev
May 12, 2026
MIXED
PRESS-RELEASE
5/10
Rezolute released expanded Phase 3 sunRIZE study data showing clinically meaningful glycemic improve
May 1, 2026
BEARISH
PRESS-RELEASE
5/10
Rezolute (RZLT) announced clinical data presentation at an upcoming medical conference but did not r
Apr 21, 2026
Current analyst consensus: Buy (75% buy). Based on 16 analysts: 6 strong buy, 6 buy, 4 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$7.11 mean target
+67.3% upside
Strong Buy (1.60)
$4.00 Low
$14.00 High
| Metric | Value |
|---|---|
| Current Price | $4.25 |
| Target Low | $4.00 |
| Target Mean | $7.11 |
| Target Median | $6.00 |
| Target High | $14.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (1.60) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Next Q 2026-09-30 |
$-0.16 | $-0.22 | $-0.12 | 12.0% | +20.0% | 2↑ 0↓ | $0.0B | 0.0% | 6 |
| Next FY 2027-06-30 |
$-0.63 | $-0.87 | $-0.45 | 9.9% | — | 4↑ 0↓ | $0.0B | 0.0% | 8 |
| Current Q 2026-06-30 |
$-0.14 | $-0.17 | $-0.11 | 45.2% | — | 3↑ 2↓ | $0.0B | 0.0% | 8 |
| Current FY 2026-06-30 |
$-0.69 | $-0.72 | $-0.67 | 29.1% | — | 4↑ 1↓ | $0.0B | 0.0% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.142 | |
| 7d ago | $-0.139 | -0.004 |
| 30d ago | $0.000 | -0.142 |
| 60d ago | $-0.167 | +0.025 |
| 90d ago | $-0.166 | +0.023 |
12 analyst firms have rated this stock: 2 upgrades, 0 downgrades, 7 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 3, 2026 | Maxim Group | MAINTAIN | Buy | Buy |
| Jun 3, 2026 | Citizens | UPGRADE | Market Perform | Market Outperform |
| Jun 3, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Jun 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 2, 2026 | BTIG | MAINTAIN | Buy | Buy |
| May 14, 2026 | Maxim Group | MAINTAIN | Buy | Buy |
| Mar 25, 2026 | Wedbush | UPGRADE | Neutral | Outperform |
| Jan 8, 2026 | Wedbush | MAINTAIN | Neutral | Neutral |
| Jan 8, 2026 | BTIG | REITERATE | Buy | Buy |
| Dec 12, 2025 | Guggenheim | MAINTAIN | Buy | Buy |
| Dec 12, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Nov 20, 2025 | BTIG | REITERATE | Buy | Buy |
| Oct 29, 2025 | Citizens | MAINTAIN | Market Outperform | Market Outperform |
| Sep 22, 2025 | Guggenheim | REITERATE | Buy | Buy |
| Sep 19, 2025 | Maxim Group | MAINTAIN | Buy | Buy |
| Sep 18, 2025 | BTIG | REITERATE | Buy | Buy |
| Sep 3, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 28, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 13, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 13, 2025 | JMP Securities | MAINTAIN | Market Outperform | Market Outperform |
| Feb 10, 2025 | Guggenheim | REITERATE | Buy | Buy |
| Feb 5, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 8, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 5, 2024 | Wedbush | INITIATE | — | Outperform |
| Aug 6, 2024 | Maxim Group | MAINTAIN | Buy | Buy |
| Aug 6, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jul 17, 2024 | BTIG | INITIATE | — | Buy |
| Jun 4, 2024 | Craig-Hallum | INITIATE | — | Buy |
| May 22, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 16, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 19, 2024 | JMP Securities | REITERATE | Market Outperform | Market Outperform |
| Apr 18, 2024 | JMP Securities | REITERATE | Market Outperform | Market Outperform |
| Apr 18, 2024 | JonesTrading | INITIATE | — | Buy |
| Apr 9, 2024 | Maxim Group | INITIATE | — | Buy |
| Mar 7, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 14, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 14, 2023 | JMP Securities | MAINTAIN | Market Outperform | Market Outperform |
| Sep 19, 2023 | Cantor Fitzgerald | REITERATE | Overweight | Overweight |
| Sep 18, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Sep 15, 2023 | JMP Securities | REITERATE | Market Outperform | Market Outperform |
| Jun 28, 2023 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Jun 28, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 19, 2023 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| May 15, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 28, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Feb 14, 2023 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Feb 13, 2023 | JMP Securities | REITERATE | — | Market Outperform |
| Sep 12, 2022 | Jefferies | INITIATE | — | Buy |
| Jun 15, 2022 | Cantor Fitzgerald | INITIATE | — | Overweight |
| Nov 29, 2021 | Canaccord Genuity | MAINTAIN | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 6 | 4 | 0 | 0 | 75% | |
| May 1, 2026 | 6 | 6 | 4 | 0 | 0 | 75% | |
| Apr 1, 2026 | 5 | 6 | 5 | 0 | 0 | 69% | |
| Mar 1, 2026 | 5 | 6 | 5 | 0 | 0 | 69% | |
| Feb 1, 2026 | 5 | 6 | 5 | 0 | 0 | 69% | |
| Jan 1, 2026 | 5 | 6 | 5 | 0 | 0 | 69% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 4, 2026
m_and_a
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
<p>REDWOOD CITY, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- <strong>Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”),</strong> a late-stag
May 19, 2026
short_volume
Short Volume: RZLT — 57.3% short (0.4M / 0.7M)
Short: 394,914 | Exempt: 26,238 | TRF Vol: 689,794 | Short Ratio: 57.3% | Off-exchange volume (dark pool + OTC)
May 12, 2026
earnings
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
<p align="justify">REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- <strong>Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”),</stro
May 11, 2026
other
Rezolute to Participate in Upcoming Investor Conferences
<p align="justify">REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- <strong>Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”),</stro
May 11, 2026
earnings_calendar
RZLT Q3 2026 Earnings Scheduled — 2026-05-11
May 6, 2026
short_volume
Short Volume: RZLT — 69.6% short (0.4M / 0.6M)
Short: 417,012 | Exempt: 119 | TRF Vol: 599,090 | Short Ratio: 69.6% | Off-exchange volume (dark pool + OTC)
May 1, 2026
earnings
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
<p align="center"><em>Includes results from additional continuous glucose monitoring (CGM)-based outcomes which demonstrate significant and consistent
Apr 24, 2026
short_volume
Short Volume: RZLT — 66.0% short (0.4M / 0.6M)
Short: 382,141 | Exempt: 494 | TRF Vol: 579,395 | Short Ratio: 66.0% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
earnings
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
<p align="center"><em>Oral presentation will include previously announced topline results as well as pre-specified and post-hoc data updates</em><br><
Mar 31, 2026
short_interest
FTD: RZLT — 245,053 shares ($0.7M) failed to deliver
Settlement: 20260331, Price: $2.85, FTD Value: $698,401.05, REZOLUTE INC COM NEW (NV)
Mar 30, 2026
short_interest
FTD: RZLT — 262,878 shares ($0.8M) failed to deliver
Settlement: 20260330, Price: $2.99, FTD Value: $786,005.22, REZOLUTE INC COM NEW (NV)
Mar 27, 2026
short_interest
FTD: RZLT — 273,029 shares ($0.9M) failed to deliver
Settlement: 20260327, Price: $3.25, FTD Value: $887,344.25, REZOLUTE INC COM NEW (NV)
Mar 4, 2026
other
Rezolute to Participate in the Citizens Life Sciences Conference
<p align="justify">REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- <strong>Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”),</st